Abstract: The present invention relates to vaccines of DNA that code for specific viral sequences. The DNA vaccines against yellow fever according to the invention are based on the sequence that codes for the yellow fever virus envelope protein (p/YFE). Besides the wild p/YFE construct, sequence E was also fused with the sequence that codes for the human lysosome-associated membrane protein (h-LAMP), generating the construct (pL/YFE). The results of the invention are considered to be very promising, since both constructs can induce T-cell response against the same epitopes induced by the 17DD vaccine, and the pL/YFE construct can also induce a satisfactory concentration of neutralizing antibodies. The pL/YFE vector was inoculated in mice, before intracerebral challenge with the virus of yellow fever. Surprisingly, 100% of the mice immunized with pL/YFE survived the challenge.

Abstract: A computer-implemented method, a computer system and a non-transitory computer-readable medium for constructing human-readable sentences from imaging data of a subject can include: receiving imaging data including image elements of at least one region of interest of the subject; segmenting the imaging data of the region of interest into a plurality of sub-regions, where each sub-region includes a portion of the image elements; calculating an abnormality factor for each of the sub-regions by quantitatively analyzing segmented image information of the imaging data of the sub-regions using data from a normal database; comparing each abnormality factor to a threshold value; constructing a human-understandable sentence for the subject when a corresponding abnormality factor exceeds the threshold, where each human-understandable sentence references a physical structure threshold associated with the calculation for the region or sub-region; and outputting the human-understandable sentences for the at least one regio

Abstract: The present disclosure provides a system with an innovative electrode designed as an RF/microwave antenna as well as methods to monitor/assess biological tissue and perform surgical procedures.

Abstract: Methods for preventing or treating subjects having cancer based on the identification of pharmaceutical agents that target cancer stem cells (CSCs) have been identified. These methods include administering to the subject an effective amount of a COX2 inhibitor and an effective amount of a YAP1 inhibitor. In addition, methods of enhancing chemotherapeutic responses in cancer patients have been discovered and are described herein.

Abstract: An example virtual capacitor including processing circuitry, a physical capacitor, and a bi-directional current source is provided. The bi-directional current source may be electrically coupled between the physical capacitor and a power distribution bus. The control circuitry may be configured to control the bi-directional current source and the physical capacitor to emulate a shunt capacitor electrically connected to the power distribution bus with a different capacitance than a capacitance of the physical capacitor by controlling a voltage across the physical capacitor to be within a physical capacitor voltage range that is different than an operating bus voltage range.

Abstract: According to one embodiment, a crystal growth method includes forming a first member at at least a part of a bottom portion of a hole in a structure body. The hole includes the bottom portion and a side portion. The first member includes a first element. The first element is not adhered to at least a part of the side portion in the forming the first member. The crystal growth method includes growing a crystal member inside the hole by supplying a source material to the hole after the forming the first member. The source material includes a second element. The crystal member includes the second element.

Abstract: Compositions for the treatment of colorectal cancer target bacterial biofilms in the gastrointestinal tract. Methods of treatment include one or more agents which target bacteria and the bacterial biofilms.

Abstract: Autoimmune diseases are thought to be initiated by exposures to foreign antigens that cross-react with endogenous molecules. Analyses of peripheral blood lymphocytes and serum suggested that mutations in autoimmune antigen targets sparked cellular immunity and cross-reactive humoral immune responses. Acquired immunity to autoimmune antigens can help control naturally occurring cancers.

Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.

Abstract: Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.

Abstract: A free-space optical (FSO) retransmission device includes a memory bank partitioned into at least a source buffer indexed by segment identifications (IDs), an interface in communication with an optical terminal and an Ethernet network, and a programmable circuit configured to execute data process operations. The data process operations include receiving data from the Ethernet network, generating an FSO segment including the data received from the Ethernet network and a segment ID, generating and transmitting an outgoing FSO frame to the optical terminal, the outgoing FSO frame including an outgoing FSO segment, and storing the outgoing FSO segment in the source buffer until a corresponding acknowledgement is received in an inbound FSO frame from the optical terminal.

Abstract: A computer-implemented method may be provided for analyzing and disseminating medical information. The method may include steps performed by one or more processors including, receiving a plurality of patient medical data; aggregating the plurality of patient medical data, wherein access to patient private health information is restricted; receiving a query for medical information; analyzing the aggregated medical data based on the query; producing a result of the query based on the analyzing of the aggregated medical data; and transmitting the result of the query.

Abstract: Methods of inducing cell death by hyperactivation of motility networks are provided.

Abstract: TERT promoter mutations occur in both papillary and flat lesion bladder cancers, are the most frequent genetic alterations identified to date in noninvasive precursor lesions of the bladder, are detectable in urine, and appear to be strongly associated with bladder cancer recurrence. The TERT promoter mutations are useful urinary biomarker for both the early detection and monitoring of bladder neoplasia.

Abstract: Impressive responses have been observed in patients treated with checkpoint inhibitory anti-PD-1 or anti-CTLA-4 antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge. Treatment with both anti-PD-1 and anti-CTLA-4 antibodies were unable to eradicate large, modestly immunogenic CT26 tumors or metastatic 4T1 tumors. However, co-treatment with epigenetic modulating drugs and checkpoint inhibitors markedly improved treatment outcomes, curing more than 80% of them. Functional studies revealed that the primary targets of the epigenetic modulators were myeloid-derived suppressor cells (MDSCs). A PI3K-inhibitor that reduced circulating MDSCs also cured 80% of mice with metastatic 4T1 tumors when combined with immune checkpoint inhibitors. Thus, cancers resistant to immune checkpoint blockade can be cured by eliminating MDSCs.

Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.

Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.

Abstract: The present invention relates to the field of post-partum depression. More specifically, the present invention relates to the use of biomarkers to diagnose post-partum depression or predict a risk thereof. In a specific embodiment, a method for identifying a likelihood of PPD in a patient comprises the steps of (a) providing a sample from the patient; (b) measuring white blood cell type counts and DNA methylation levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises HP1BP3 and TTC9B and the white blood cell type counts comprise monocytes and non-monocytes; and (c) identifying the patient as likely to develop PPD based on the relative DNA methylation levels at the biomarker loci relative to the ratio of monocytes:non-monocytes.

Abstract: Provided are compositions and methods for compound discovery. Modified yeast that have their endogenous yeast shikimate pathway disrupted or deleted, and replaced with homologous pathway genes from one or more distinct organisms, are provided and used in assays of test agents. The homologous pathway genes are designed to supplement the disrupted or deleted shikimate pathway genes. The assays are designed to identify whether or not the test agents can interfere with the function of enzymes in the shikimate pathway from organisms that are distinct from the yeast avatar hosts. In embodiments, the disruption/deletion of the yeast endogenous shikimate pathway results in the yeast being incapable of producing chorismic acid.

Abstract: Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter and astrocyte elevated gene 1 (AEG-1) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols, e.g. for imaging and/or treating spontaneous metastasis. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.